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ABSTRACT 
Objective: The main purpose of this work was to elucidate the effect of certain formulation factors on the size of nanostructured lipid carriers 
(NLCs) and nanoemulsions (NEs) by using high shear homogenization method. 
Methods: NLCs and NEs were prepared by high shear homogenization method using different liquid lipids types such as (Dermarol DCO® and 
Dermarol CCT®) at different concentrations. The effect of different concentration ratios of Tween 80 to Span 20 (2.5/1, 5/1, 10/1, 15/1) w/w % 
and different homogenization speeds (12 000, 18 000 rpm) on the resulted particle size were also studied. 
Results: The results revealed that the optimum NLCs and NEs resulted when we use Dermarol CCT® with a concentration of 90 % as liquid lipid 
and decreasing surfactant ratio to (2.5/1) w/w % with increasing the homogenization speed to 18 000 rpm.  
Conclusion: NLCs and NEs were successfully prepared, and from this study, it can be concluded that NLCs have the optimum particle size than 
Nanoemulsions. 
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In recent years, it has got to be clear that the advancement of novel 
medications is deficient for ensuring the advancement in medical 
treatment. The data obtained in the in vitro studies are often trailed 
by disappointing results in the in vivo or clinical circumstance. 
Predominant reasons for this failure are the insufficient drug level In 
the body due to its rapid metabolism, the high medication poisonous 
quality in view of broad distribution, and a high fluctuation of 
plasma medication levels [1]. 
A few methodologies have recently been explored to create nanosized 
drug delivery systems. These systems can be partitioned into two 
gatherings: polymeric and lipid systems [2]. The quantity of items in 
view of polymeric nanoparticles in the business sector is restricted in 
light of the poisonous quality of polymers, what's more, the absence of 
suitable expansive scale generation strategies. All together to conquer 
these issues, a lot of hope has been centred on lipid-based carriers, for 
example, nanoemulsions (NEs) and nanostructured lipid carriers 
(NLCs). NEs are medication conveyance systems comprising of 
emulsified oil and water systems with mean droplet diameters ranging 
from 50 to 1000 nm. Generally, the normal droplet size is somewhere 
around 100 and 500 nm and can exist as oil-in-water (o/w) or water-
in-oil (w/o) form, where the internal phase is either oil or water, 
separately [3, 4]. These systems have points of interest for medication 
conveyance, for example, the utilization of physiologically tolerated 
lipids, large-scale production, prevent the medications from 
destruction, enhanced bioavailability, and controlled-release qualities 
[5]. The flaws of NEs are poor drug loading capacities, medication 
deterioration during storage and they have physical instability that can 
be increased by the joined drug [6, 7]. NLCs made out of a strong lipid 
matrix with a certain content of a fluid lipid are another era of lipid 
nanoparticles. NLCs are viewed as a more advanced era of 
nanoparticles, which have enhanced properties for drug loading, 
adjustment of the delivery profile, and stable medication during 
storage [8-11]. Because of the lipophilic content of the NLCs, they are 
considered especially helpful in the administration of lipophilic 
medications. 
Broadly speaking, energy is normally required in emulsion 
formulation in light of the fact that the procedure may be non-
spontaneous. The creation of nanoemulsions expenses more energy 
than that required to deliver macroemulsions [12].  
High-energy emulsification routines make utilization of instruments 
that use high mechanical energy to make nanoemulsions with high 
kinetic energy. The mechanical instruments make serious disruptive 
forces which separate the oil and water stages to make Nano-sized 
droplets. This can be accomplished with ultrasonicators, micro 
fluidizer and high shear Homogenizers [13-15]. Molecule size here 
will rely on the type of instruments utilized and their working 
conditions like time and temperature alongside sample properties 
and compositions [16].  
The objective of the present work was to study the effect of certain 
formulation factors on the size of NLCs and NEs in order to realize 
the optimum formulation factors that give the optimum particle size. 
MATERIALS AND METHODS 
Materials 
Naterol GMS® (Glyceryl stearate) as solid lipid, Dermarol DCO® is 
an ester of decyl alcohol and oleic acid (Decyl Oleate), Dermarol 
CCT® ® is a mixed triester of glycerin and Caprylic and Capric acids 
(Caprylic/Capric triglyceride) as liquid lipids and Tween 80® 
(Polysorbate80) as-surfactant were obtained from CISME Italy s. n. c. 
via Marcora, Milano-Italy. Span 20® (Sorbitan monolaurate) as-
surfactant, and Lecithin® (cosurfactant). All other chemicals are of 
HPLC grade.  
Preparation of NLCs and NEs 
NLCs and NEs were prepared by high shear hot homogenization 
method [17, 18]. Briefly, the lipid phase consisted of Naterol GMS, as 
solid lipid in case of NLC was melted at 80 °C and then mixed with 
the liquid lipid Dermarol DCO®or Dermarol CCT® and added to the 
Oily surfactants (Span 20 and Lecithin), or the liquid lipids Dermarol 
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DCO® or CCT® Dermarol CCT® in case of NE was added to the Oily 
surfactants (Span 20 and Lecithin). An aqueous surfactant phase 
consists of Tween 80 was heated up to the same temperature of the 
molten lipid phase. The hot surfactant solution was poured onto the 
hot lipid phase and homogenization was carried out at 12, 000 or 18, 
000 rpm for 4 cycles (2 min with 30 s off) using high shear 
homogenizer (IKA T25 digital Ultra–Turrax Germany), Then leave to 
cool to room temperature. 
 
Table 1: NLC prepared at 12 000 and 18 000 rpm using liquid lipid dermarol DCO® and different surfactant ratio 
NLC formula code prepared at 12 000 
rpm 




Dermarol DCO®  
(w/w%) 
Tween/Span 
NLC1 NLC1* 90% 10% 2.5/1 
 NLC2 NLC2* 80% 20% 
NLC3 NLC3* 70% 30% 
NLC4 NLC4* 60% 40% 
NLC5 NLC5* 50% 50% 
NLC6 NLC6* 40% 60% 
NLC7 NLC7* 30% 70% 
NLC8 NLC8* 20% 80% 
NLC9 NLC9* 10% 90% 
NLC1 NLC1* 90% 10% 5/1 
 NLC2 NLC2* 80% 20% 
NLC3 NLC3* 70% 30% 
NLC4 NLC4* 60% 40% 
NLC5 NLC5* 50% 50% 
NLC6 NLC6* 40% 60% 
NLC7 NLC7* 30% 70% 
NLC8 NLC8* 20% 80% 
NLC9 NLC9* 10% 90% 
NLC1 NLC1* 90% 10% 10/1 
 NLC2 NLC2* 80% 20% 
NLC3 NLC3* 70% 30% 
NLC4 NLC4* 60% 40% 
NLC5 NLC5* 50% 50% 
NLC6 NLC6* 40% 60% 
NLC7 NLC7* 30% 70% 
NLC8 NLC8* 20% 80% 
NLC9 NLC9* 10% 90% 
NLC1 NLC1* 90% 10% 15/1 
 NLC2 NLC2* 80% 20% 
NLC3 NLC3* 70% 30% 
NLC4 NLC4* 60% 40% 
NLC5 NLC5* 50% 50% 
NLC6 NLC6* 40% 60% 
NLC7 NLC7* 30% 70% 
NLC8 NLC8* 20% 80% 
NLC9 NLC9* 10% 90% 
 
Table 2: NLC formulae prepared at 12 000 and 18 000 rpm using liquid lipid Dermarol CCT® and different surfactant ratio 
NLC Formula code 
prepared at 12 000 rpm 





NLC10 NLC10* 90% 10% 2.5/1 
NLC11 NLC11* 80% 20% 
NLC12 NLC12* 70% 30% 
NLC13 NLC13* 60% 40% 
NLC14 NLC14* 50% 50% 
NLC15 NLC15* 40% 60% 
NLC16 NLC16* 30% 70% 
NLC17 NLC17* 20% 80% 
NLC18 NLC18* 10% 90% 
NLC10 NLC10* 90% 10% 5/1 
 NLC11 NLC11* 80% 20% 
NLC12 NLC12* 70% 30% 
NLC13 NLC13* 60% 40% 
NLC14 NLC14* 50% 50% 
NLC15 NLC15* 40% 60% 
NLC16 NLC16* 30% 70% 
NLC17 NLC17* 20% 80% 
NLC18 NLC18* 10% 90% 
NLC10 NLC10* 90% 10% 10/1 
 NLC11 NLC11* 80% 20% 
NLC12 NLC12* 70% 30% 
NLC13 NLC13* 60% 40% 
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NLC14 NLC14* 50% 50% 
NLC15 NLC15* 40% 60% 
NLC16 NLC16* 30% 70% 
NLC17 NLC17* 20% 80% 
NLC18 NLC18* 10% 90% 
NLC10 NLC10* 90% 10% 15/1 
 NLC11 NLC11* 80% 20% 
NLC12 NLC12* 70% 30% 
NLC13 NLC13* 60% 40% 
NLC14 NLC14* 50% 50% 
NLC15 NLC15* 40% 60% 
NLC16 NLC16* 30% 70% 
NLC17 NLC17* 20% 80% 
NLC18 NLC18* 10% 90% 
 
Table3: NE formulae prepared at 12 000 and 18 000 rpm using different concentrations of liquid lipids Dermarol DCO®, Dermarol CCT® 
and different surfactant ratio 
NE Formula code 
prepared at 12 000 rpm 
NE Formula code prepared at 






NE1 NE1* 90% 10% 2.5/1 
NE2 NE2* 80% 20% 
NE3 NE3* 70% 30% 
NE4 NE4* 60% 40% 
NE5 NE5* 50% 50% 
NE6 NE6* 40% 60% 
NE7 NE7* 30% 70% 
NE8 NE8* 20% 80% 
NE9 NE9* 10% 90% 
NE1 NE1* 90% 10% 5/1 
 NE2 NE2* 80% 20% 
NE3 NE3* 70% 30% 
NE4 NE4* 60% 40% 
NE5 NE5* 50% 50% 
NE6 NE6* 40% 60% 
NE7 NE7* 30% 70% 
NE8 NE8* 20% 80% 
NE9 NE9* 10% 90% 
NE1 NE1* 90% 10% 10/1 
 NE2 NE2* 80% 20% 
NE3 NE3* 70% 30% 
NE4 NE4* 60% 40% 
NE5 NE5* 50% 50% 
NE6 NE6* 40% 60% 
NE7 NE7* 30% 70% 
NE8 NE8* 20% 80% 
NE9 NE9* 10% 90% 
NE1 NE1* 90% 10% 15/1 
 NE2 NE2* 80% 20% 
NE3 NE3* 70% 30% 
NE4 NE4* 60% 40% 
NE5 NE5* 50% 50% 
NE6 NE6* 40% 60% 
NE7 NE7* 30% 70% 
NE8 NE8* 20% 80% 
NE9 NE9* 10% 90% 
 
Particle size analysis 
Particle size analysis of NLC and NE were carried out using Laser 
diffraction particle size analyzer (LD, Master size Malvern 
Instruments Ltd. Worcestershire. UK) at 25 ℃. Before the analysis 
carried out, samples were diluted using distilled water. 
RESULTS AND DISCUSSION 
Preparation of NLCs and NEs 
Different methods are used for the preparation of NLCs and NEs [19, 
20]. In the present study, we had adopted a cost-effective, simple 
and reproducible method for the preparation of nanoemulsions, i.e. 
High shear homogenization method [17, 18]. 
NLCs were composed of 5(w/w %) Naterol GMS and Dermarol 
DCO® or Dermarol CCT® used in different concentrations and 
stabilized by 1(w/w %) Lecithin as co-surfactant and different ratios 
of surfactant concentrations Tween 80 and Span 20 (2.5/1, 5/1, 
10/1, 15/1) w/w %, while NEs were composed of 5(w/w %) 
Dermarol DCO® and Dermarol CCT® used in different 
concentrations and stabilized by 1(w/w %) Lecithin as co-surfactant 
and different ratios of surfactant concentrations Tween 80 and Span 
20 (2.5/1, 5/1, 10/1, 15/1) w/w %. 
Effect of surfactants ratios on particle size 
Fig. [1-12] presents the obtained results for the effect of surfactant 
ratio on the particle size of NEs and NLCs. firstly fig. 1, 2 demonstrate 
that the best NEs obtain by using the surfactant concentration ratio 
2.5/1 (w/w %), While fig. 3,4 demonstrate that the best NLC obtained 
by using the surfactant concentration ratio (5/1), (2.5/1) w/w %. A 
similar results were reported by Wulff-Perez et al. [21] who found that 
at high surfactant concentrations, some surfactant molecules may 
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increase the local osmotic pressure, which causes moving of 
continuous phase between some droplets to them, and this cause 
depletion of the continuous phase between the drops and the 
aggregation happened and so the particle size increase. While different 
results were reported by Chanana et al.[22] Who found that increasing 
surfactant concentration leads to decrease in particle size of 
nanoparticles. Fig. [5-12] presents the effect of each surfactant 
concentration ratio on the particle size of NEs and NLCs. 
 
 








Fig. 3: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) prepared using homogenization speed at 12 
000 rpm (mean±SD, N=3) 




Fig. 4: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) prepared using homogenization speed at 18 
000 rpm (mean±SD, N=3) 
 
 
Fig. 5: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared using 
homogenization speed at 12 000 rpm (mean±SD, N=3) 
 
 
Fig. 6: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared using 
homogenization speed at 12 000 rpm (mean±SD, N=3) 




Fig. 7: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared using 
homogenization speed at 12 000 rpm (mean±SD, N=3) 
 
 
Fig. 8: Effect of certain surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared 
using homogenization speed at 12 000 rpm (mean±SD, N=3) 
 
 
Fig. 9: Effect of certain surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared 
using homogenization speed at 18 000 rpm (mean±SD, N=3) 




Fig. 10: Effect of certain surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared 
using homogenization speed at 18 000 rpm (mean±SD, N=3) 
 
 
Fig. 11: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared using 
homogenization speed at 18 000 rpm (mean±SD, N=3) 
 
 
Fig. 12: Effect of surfactant ratio on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared using 
homogenization speed at 18 000 rpm (mean±SD, N=3) 
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Effect of lipid type and concentration 
Normally NEs formulate by using two liquid lipids only without solid 
lipid, While NLCs formulate by using solid lipid and liquid lipid, so 
we studied the effect of lipid concentrations on NEs particle size and 
the effect of lipid type and concentration on NLCs particle size. In 
our study, we used two liquid lipids Dermarol DCO® and Dermarol 
CCT® in different concentration to prepare NEs and the same liquid 
lipids each one separately with Naterol GMS as solid lipid to prepare 
NLCs.  
Fig. [13–28] presents the obtained results of the effect of lipid type 
and concentration on the size of particles. Fig. [13,14, 16-17,19 and 
20] demonstrate that NLCs prepared by using liquid lipid dermarol 
CCT® gave the smallest NLCs particle size, but only figs. 15 and 18 
demonstrate that the best NLCs particle size resulted with Dermarol 
DCO® as liquid lipid, the study presents that by increasing the 
concentration of liquid lipid the particle size of NLCs decrease. A 
similar results were reported by Puglia, et al. and (Mu and Feng, 
2003) who suggested that the addition of liquid lipid to solid lipid 
tends to promote the formation of small particle population, which 
may be due to increasing in molecular mobility of the matrix after 
liquid oil addition [23, 24]. Different results were reported by 
Soleimanian et al. [25] who suggested that particle size increase by 
increasing the liquid oil concentrations due to the more disordered 
crystalline structure inside the nanoparticles. Fig. [21-28] 
comparisons between NEs and NLCs prepared at different 
homogenization speed. It was found that the best NEs resulted when 
we increase Dermarol CCT® concentration and decrease Dermarol 
DCO® concentration, while the best NLCs obtained when we use 
Dermarol CCT® as liquid lipid. 
 
 
Fig. 13: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(2.5/1) (mean±SD, N=3) 
 
 
Fig. 14: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(5/1) (mean±SD, N=3) 
 
 
Fig. 15: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(10/1) (mean±SD, N=3) 




Fig. 16: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(15/1) (mean±SD, N=3) 
 
 
Fig. 17: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and prepared with a surfactant 
ratio (2.5/1) (mean±SD, N=3) 
 
 
Fig. 18: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(5/1) (mean±SD, N=3) 
 
 
Fig. 19: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(10/1) (mean±SD, N=3) 




Fig. 20: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) prepared with a surfactant ratio 
(15/1) (mean±SD, N=3) 
 
 
Fig. 21: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (2.5/1) (mean±SD, N=3) 
 
 
Fig. 22: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (5/1) (mean±SD, N=3) 




Fig. 23: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (10/1) (mean±SD, N=3) 
 
 
Fig. 24: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (15/1) (mean±SD, N=3) 
 
 
Fig. 25: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (2.5/1) (mean±SD, N=3) 




Fig. 26: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (5/1) (mean±SD, N=3) 
 
 
Fig. 27: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (10/1) (mean±SD, N=3) 
 
 
Fig. 28: Effect of lipid type and concentration on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) 
prepared with a surfactant ratio (15/1) (mean±SD, N=3) 




Fig. 29: Effect of homogenization speed on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared 
with a surfactant ratio (2.5/1) (mean±SD, N=3) 
 
 
Fig. 30: Effect of homogenization speed on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions (NEs) prepared 
with a surfactant ratio (5/1) (mean±SD, N=3) 
 
 
Fig. 31: Effect of homogenization speed on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions (NEs) prepared 
with a surfactant ratio (10/1) (mean±SD, N=3) 
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Effect of homogenization speed 
Results of the effect of homogenization speed on the particle size of 
NEs and NLCs are illustrated in fig. [29–32]. This fig. reveal that 
increasing the homogenization speed from 12 000 to 18 000 rpm. 
Led to decrease the particle size of NEs and NLCs.  
A similar result was obtained by Kovacevic et al. [26] who found that 
smaller particle size are obtained by increasing the homogenization 
speed which may be attributable to the increased force of deforming 
droplets at higher speed results in a decrease of particles. A different 
result was obtained by Lander et al. [27] who found that smaller 
particle sizes are acquired by increasing the processing temperatures 
because of the lowered viscosity of the lipid phase, the increase of the 
homogenization speed resulted in an increase of the particle size due 
to particle coalescence, this occurred because of the high kinetic 
energy of the particles. It was found that the best NEs and NLCs 
particle size obtained at homogenization speed 18 000 rpm.  
NLCs formulated at surfactant concentration ratio 2.5/1 (w/w %) 
present that the mean particle size of the resulted formulations when 
using homogenization speed 12 000rpm ranging from 1623 nm to 179 
nm while the mean particle size of the resulted formulations when using 
homogenization speed 18 000 rpm ranging from 1795 nm to 158 nm. 
 
 
Fig. 32: Effect of homogenization speed on the particle size of nanostructured lipid carriers (NLCs) and nanoemulsions(NEs) prepared 
with a surfactant ratio (15/1) (mean±SD, N=3) 
 
CONCLUSION 
Different formulative of factors which influenced the size of particles of 
NEs and NLCs prepared by high shear homogenization method were 
successfully studied. The results suggested the importance of controlling 
the critical formulation and process parameters during formulation such 
as (type of liquid lipids, homogenization speed, and surfactant 
concentration ratio) as they greatly affected the particle size of the final 
prepared nanoparticles. The optimum NLCs resulted when we use 
Dermarol CCT® as liquid lipid and surfactant ratio 2.5/1(w/w %) with 
homogenization speed 18 000 rpm or with a surfactant ratio 10/1 (w/w 
%) and homogenization speed 12 000 rpm. While the optimum NEs 
obtained when we increase Dermarol CCT® concentration and use 
surfactant ratio 2.5/1(w/w %) with homogenization speed 18 000 rpm. 
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